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Aims. To examine the antioxidant and anti-inflammatory effects of pomegranate polyphenols in obese patients with type 2 diabetes
(T2DM) (𝑛 = 8) and in healthy nondiabetic controls (𝑛 = 9).Methods. Participants received 2 capsules of pomegranate polyphenols
(POMx, 1 capsule = 753mg polyphenols) daily for 4 weeks. Blood draws and anthropometrics were performed at baseline and
at 4 weeks of the study. Results. Pomegranate polyphenols in healthy controls and in T2DM patients did not significantly affect
body weight and blood pressure, glucose and lipids. Among clinical safety profiles, serum electrolytes, renal function tests, and
hematological profiles were not significantly affected by POMx supplementation. However, aspartate aminotransferase (AST)
showed a significant increase in healthy controls, while alanine aminotransferase (ALT) was significantly decreased in T2DM
patients at 4 weeks (𝑃 < 0.05), though values remained within the normal ranges. Among the biomarkers of lipid oxidation and
inflammation, oxidized LDL and serum C-reactive protein (CRP) did not differ at 4 weeks in either group, while pomegranate
polyphenols significantly decreased malondialdehyde (MDA) and hydroxynonenal (HNE) only in the diabetic group versus
baseline (𝑃 < 0.05). Conclusions. POMx reduces lipid peroxidation in patients with T2DM, but with no effects in healthy controls,
and specifically modulates liver enzymes in diabetic and nondiabetic subjects. Larger clinical trials are merited.
1. Introduction
Among the fruits with demonstrated cardiovascular ben-
efits, the pomegranate (Punica granatum L.) has gained
significant attention in complementary and alternative health
practices. Pomegranate juice has been rated to possess the
highest antioxidant capacity when compared to the com-
monly consumed polyphenol-rich beverages in the United
States [1]. Several categories of phytochemicals are present
in the pomegranate including flavonoids (flavonols, flavanols,
and anthocyanins), condensed tannins (proanthocyanidins),
and hydrolysable tannins (ellagitannins and gallotannins).
Additional phytochemicals present in pomegranates include
organic and phenolic acids, sterols and triterpenoids, and
alkaloids. The seeds of the pomegranate are rich in crude
fibers, pectin, and sugars [2, 3]. Thus, pomegranate polyphe-
nols in cell culture, animal model systems, and limited
clinical research have been reported to exert several vascular
benefits, including antioxidant and anti-inflammatory effects
[2, 3]. Pomegranate juice supplementation has been shown to
ameliorate hypertension and reduce surrogate risk factors of
atherosclerosis in a few clinical studies [4–8]. However, the
safety as well as efficacy of pomegranate polyphenol extracts,
especially as commercially available dietary supplements in
the United States, needs further investigation in healthy
subjects as well as in those with cardiovascular risk factors.
Obesity and type 2 diabetes (T2DM) are significant public
health problems in theUnited States and have been associated
with several modifiable factors, including dietary selection
of foods and beverages. The role of nutraceuticals, including
pomegranate polyphenols, in the therapeutic management of
these conditions has been identified in the reported literature,
though the evidence is largely based on studies in cell culture
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and animal models [9, 10]. In a single clinical study reported
byHeber et al. (2007) in overweight individuals, ellagitannin-
enriched pomegranate polyphenol extracts were shown to
be well tolerated and decrease plasma thiobarbituric acid
reactive substances (TBARS), a biomarker of lipid oxidation
at 4 weeks of supplementation [11]. However, this study
excluded subjects with diabetes and hypertension and did
not investigate the effects of pomegranate polyphenols on
other notable biomarkers of oxidative stress and inflamma-
tion, such as oxidized LDL and C-reactive protein (CRP)
[11]. Thus, as highlighted in a recently published review by
Medjakovic and Jungbauer (2013), the role of pomegranates
in reducing cardiovascular risks needs to be further examined
and clarified in clinical studies [10]. Thus, the present pilot
clinical study was conducted to examine the effects of a 4-
week supplementation of pomegranate polyphenol extracts
(POMx) on body weight, blood pressure, clinical variables,
and biomarkers of lipid oxidation and inflammation in obese
adults with type 2 diabetes and in healthy controls.
2. Materials and Methods
2.1. Study Design and Subjects. This was a 4-week pre-
and postintervention study investigating the effects of
pomegranate polyphenol supplementation (POMx capsules,
Pom Wonderful, CA, USA), in subjects with T2DM and in
healthy volunteers. This study was conducted according to
the guidelines presented in the Declaration of Helsinki and
approval was obtained from the Institutional Review Board
(IRB) at the Oklahoma State University (OSU) for all proce-
dures. All participants provided a signed informed consent
prior to enrollment in the study. Subjects were recruited at the
Department of Nutritional Sciences at OSU through campus
e-mail advertisements and flyer. Participants in the diabetic
group (T2DM) were required to meet the following criteria:
diagnosis of type 2 diabetes as defined by the American
Diabetes Association (ADA) [12], abdominal adiposity (waist
circumference >35 inches in women and >40 inches in men),
and stable on oral hypoglycemic agents. Healthy controls
were recruited based on a waist circumference of less than
35 inches for women and less than 40 inches for men, and
without any diagnosis of chronic disease, such as diabetes,
cancer, or any other form of cardiovascular disease. Subjects
in both groups were excluded if they were pregnant, nurs-
ing, taking mega doses of antioxidants/fish oil supplements
(>1 g/day), and having an abnormal hematological profiles,
abnormal liver, kidney, and thyroid function tests. Individuals
who smoked or used any other formof tobaccowere excluded
as well as those who consumed alcohol on a daily basis.
The participants were supplemented with a daily dose of
two POMx capsules (1 capsule = 753mg polyphenols) for a
period of four weeks. The POMx capsules were purchased
from Pom Wonderful LLC (Los Angeles, CA, USA). Table 1
shows the composition of the two pomegranate extract cap-
sules administered to the study participants. Total phenolics
and total ellagic acid content were determined by Brunswick
Laboratories (Norton, MA, USA). Contents of moisture,
ash, protein, fat, and carbohydrate were determined by the
Table 1: Composition of POMx capsules1.
Component (weight) Weight
Carbohydrates (mg) 1801
Hexane extract (fat) (mg) 5.86
Protein (mg) 72.5
Ash (mg) 112.6
Moisture (mg) 116.08
Total ellagic acid (mg) 372
Total phenolics (mg)∗ 1505.28
1Data presented per 2101mg (2 capsules). Source: Pom Wonderful (Los
Angeles, CA, USA).
∗Expressed as mg gallic acid equivalents.
Robert M. Kerr Food and Agriculture Products Center,
OSU (Stillwater, OK, USA). The participants were asked to
consume 2 capsules, one in the morning and one in the
evening with water only.
Participants were asked to restrict intake of commonly
consumed polyphenol-containing foods for 2 weeks prior
to the start of the intervention. Blood draws and measures
of blood pressure and anthropometrics (height, weight, and
waist circumference) were obtained at the initial screening
visit (week 0) and at end of the study (week 4) for both
diabetic patients and healthy controls. Subjects were asked to
maintain their usual diet, physical activity, and lifestyle dur-
ing the study. Subjects were instructed to complete detailed
3-day food records during the first and the fourth weeks of
the study. Participants were instructed on how to use the
food records and also how to accurately record food por-
tions consumed. Venipuncture was conducted by a certified
phlebotomist at the StillwaterMedical Center (Stillwater, OK,
USA) and plasma and serum samples were separated and
stored at −80∘C for future analyses. Compliance was assessed
using pill counts and plasma ellagic acid measured using a
previously published procedure [13].
2.2. Blood Pressure. Systolic and diastolic blood pressure
measurements were obtained using a portable blood pressure
device with arm cuff, Spot Vital Signs Device (Welch Allyn,
Skaneateles Falls, NY, USA). The average of three measure-
ments was taken at an interval of 5–7 minutes.
2.3. Anthropometrics. The Health-o-Meter Weight Tracking
Scale (Sunbeam Products, Inc., Maitland, FL, USA) was used
to determine the participant’s body weight and the Gulick
II tape measure (Vital Signs, Gay Mills, WI, USA) was used
to measure waist circumference at the super iliac crest in
inches. Height was measured without shoes by using the
Accustat Genentech Stadiometer (San Francisco, CA, USA),
and height was recorded to the nearest 0.1 cm.
2.4. Clinical Variables. Freshly drawn blood samples from
baseline andweek four of the studywere analyzed for glucose,
lipids, insulin, HbA1c, CRP, safety profiles including serum
proteins, electrolytes, liver, kidney, and thyroid function tests,
and hematology at the Stillwater Medical Center (Stillwater,
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OK, USA). Serum oxidized LDL was measured in trip-
licate using an oxidized LDL competitive ELISA (Merco-
dia, Uppsala, Sweden) and serum malondialdehyde and 4-
hydroxynonenal (MDA and HNE) were determined with the
Bioxytech LPO-586 assay (OxisResearch Inc., Foster City,
CA, USA). The interassay coefficient of variation was within
8–10% for these assays.
2.5. Dietary Analysis. Participants’ 3-day food records were
used to examine any dietary changes during the course of
the 4-week study. Food record analyses were performed using
ESHA Food Processor version 9.1.0 (ESHA Research Inc.,
Salem,OR,USA).The average of 3-day intakes was calculated
at baseline and week 4 of the study.
2.6. Statistical Analysis. Descriptive statistics were calculated
and data graphed for outliers. Data have been reported as
means ± standard deviations. Our primary comparison was
the differences in means at 0 and 4 weeks of the study within
each group of T2DM and healthy non-diabetic controls.
Thus, paired t-tests were performed to determine differences
between pre- (week 0) and postintervention (week 4) values
within each group. All variables were normally distributed
and no transformation was used. Statistical significance was
set at 𝑃 < 0.05 (two-sided test) and all data analysis was
performed with SPSS version 16.0 (SPSS Inc., Chicago, IL,
USA).
3. Results
Table 1 shows the nutritional composition of the POMx
supplementation. We found a lower content of polyphenols
per capsule in comparison to the label claim of 1000mg total
polyphenols by the manufacturers (PomWonderful, LA, CA,
USA). The POMx capsules were also a significant source of
ellagic acid and carbohydrates, but a negligible source of fats
and proteins. Table 2 shows the baseline characteristics of
our study subjects. All nine healthy controls in our study
had an overall healthy BMI (<25), waist circumference less
than 35 inches, not on any medications for hypertension and
diabetes, but a significant proportion was using multivitamin
and/or mineral supplements on a regular basis. On the
other hand, among patients with T2DM, two out of eight
were males, prevalence of obesity was high as assessed by
BMI (>30) and waist circumference, 75% of patients were
controlling their glucose levels with oral hypoglycemic agents
and the remaining with diet and exercise, and 50%were using
multivitamin and/or mineral supplements on a regular basis.
None of our patients with T2DM were on insulin therapy.
Pill count showed 100% compliance and plasma ellagic acid
was detectable in approximately 85% of our participants at 4
weeks of intervention.
As shown in Table 3, POMx supplementation did not
significantly affect glucose, HbA1c, blood pressure, and lipids
at 4 weeks versus baseline in healthy controls as well as in
T2DM patients. Table 4 lists the safety profiles measured in
our study participants which were not significantly affected
by POMx supplementation, except a small but significant
Table 2: Baseline characteristics of healthy controls and subjects
with type 2 diabetes (T2DM).
Characteristic Healthy controls T2DM subjects
Gender
Male/female (𝑛/𝑛) 0/9 2/6
Age (mean, SD) 47.1, 6.3 52.4, 13.3
Weight kg (mean, SD) 62.6, 10.3 99.3, 29.1
Height cm (mean, SD) 163.7, 6.0 167.6, 7.2
BMI kg/m2 23.3, 3.0 35.3, 10.3
Waist circumference inches
(mean, SD) 31.06, 2.3 42.4, 7.9
Supplement use (%) 7 (78%) 4 (50%)
Vitamin/mineral (%) 7 (78%) 4 (50%)
Herb or botanical (%) 0 (0%) 0 (0%)
Antioxidant in the past (%) 2 (22%) 1 (13%)
Fish oil (%) 1 (11%) 1 (13%)
Blood pressure medication (%) 0 (0%) 2 (25%)
Diabetic medication (%) 0 (0%) 6 (75%)
Diabetes duration (years) N/A 3.5
Aspirin use (%) 0 (0%) 1 (13%)
Other medications (%) 1 (11%) 6 (75%)
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Figure 1: Serum oxidized LDL in healthy controls (𝑛 = 9) and
in patients with type 2 diabetes (𝑛 = 8) before and after (4
weeks) pomegranate polyphenol supplementation. Data presented
as mean ± SD.
increase in aspartate aminotransferase (AST) in healthy
controls, and also a small but significant decrease in alanine
aminotransferase (ALT) in T2DM patients at 4 weeks versus
baseline (𝑃 < 0.05). However, values of AST and ALT
remained within the normal clinical range defined in our
study at baseline and at 4 weeks (AST: 14–36U/L; ALT: 7–
56U/L).
Among the biomarkers of lipid oxidation, no significant
differences were noted in oxidized LDL (Figure 1), while
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Table 3: Effects of POMx on blood glucose, blood pressure, and lipids1.
Variables Healthy controls (𝑛 = 9) T2DM subjects (𝑛 = 8)
Screen Week 4 Screen Week 4
Fasting glucose (mg/dL) 85.11 ± 4.48 85.67 ± 8.03 105.88 ± 29.57 114.25 ± 33.36
Mean blood glucose (mg/dL) 97.33 ± 16.93 97.33 ± 19.01 121.25 ± 16.73 116.38 ± 11.56
Hemoglobin A1C (%) 5.51 ± 0.51 5.51 ± 0.57 6.22 ± 0.50 6.08 ± 0.35
Glycosylated hemoglobin (%) 6.45 ± 0.76 6.45 ± 0.85 7.51 ± 0.75 7.31 ± 0.53
Insulin (U/L) 7.77 ± 2.44 10.52 ± 12.06 18.61 ± 7.30 19.06 ± 6.03
Systolic blood pressure (mmHg) 114.67 ± 6.18 115.33 ± 5.81 129.00 ± 18.19 134.25 ± 23.81
Diastolic blood pressure (mmHg) 71.33 ± 7.37 72.67 ± 9.25 81.63 ± 8.25 79.88 ± 5.17
Total cholesterol (mg/dL) 187.89 ± 30.16 195.56 ± 30.53 182.13 ± 40.47 181.50 ± 36.73
Triglycerides (mg/dL) 77.11 ± 18.43 77.56 ± 26.88 149.75 ± 94.73 135.63 ± 66.06
LDL-cholesterol (mg/dL) 109.22 ± 27.87 117.22 ± 30.05 87.50 ± 43.09 103.75 ± 27.42
HDL-cholesterol (mg/dL) 63.11 ± 7.56 62.89 ± 9.35 51.75 ± 11.45 50.38 ± 11.03
VLDL-cholesterol (mg/dL) 15.33 ± 3.67 15.44 ± 5.29 30.00 ± 19.04 27.25 ± 13.32
LDL/HDL ratio 1.76 ± 0.52 1.93 ± 0.66 1.98 ± 0.68 2.15 ± 0.75
Total cholesterol/HDL ratio 2.89 ± 0.78 3.05 ± 0.88 3.63 ± 0.92 3.58 ± 0.96
1Data are mean ± SD; T2DM: type 2 diabetes mellitus.
Table 4: Effects of POMx supplementation on safety parameters1.
Variables Healthy controls (𝑛 = 9) T2DM subjects (𝑛 = 8)
Screen Week 4 Screen Week 4
Aspartate aminotransferase (U/L) 21.78 ± 4.29 25.33 ± 6.82∗ 30.00 ± 9.71 30.75 ± 9.42
Alanine aminotransferase (U/L) 25.33 ± 8.23 27.22 ± 11.94 36.88 ± 13.47 33.13 ± 10.05∗
Alkaline phosphatase (U/L) 72.89 ± 8.23 74.22 ± 24.79 91.50 ± 17.96 87.50 ± 11.07
Bilirubin, total (mg/dL) 0.43 ± 0.26 0.39 ± 0.24 0.33 ± 0.10 0.43 ± 0.18
Total protein (g/dL) 6.94 ± 0.32 6.96 ± 0.38 7.15 ± 0.33 7.23 ± 0.44
Albumin (g/dL) 4.18 ± 0.31 4.20 ± 0.25 4.14 ± 0.32 4.19 ± 0.32
Globulin (g/dL) 2.78 ± 0.29 2.76 ± 0.22 3.00 ± 0.21 3.05 ± 0.21
Albumin/globulin ratio 1.51 ± 0.20 1.53 ± 0.14 1.40 ± 0.17 1.38 ± 0.12
Sodium (mEq/L) 139.78 ± 1.79 139.89 ± 2.67 140.38 ± 3.02 140.50 ± 2.73
Potassium (mEq/L) 4.28 ± 0.42 4.21 ± 0.31 4.25 ± 0.18 4.25 ± 0.37
Chloride (mEq/L) 106.56 ± 2.60 107.56 ± 1.67 105.00 ± 1.20 105.50 ± 1.31
Calcium (mg/dL) 9.60 ± 0.46 9.40 ± 0.44 9.51 ± 0.52 9.49 ± 0.39
Thyroxine (T4) (ug/dL) 6.91 ± 1.55 6.42 ± 1.47 8.14 ± 2.20 7.70 ± 1.55
T3 Uptake (%) 31.22 ± 3.31 31.56 ± 3.48 29.10 ± 1.70 30.79 ± 2.75
Blood urea nitrogen (mg/dL) 12.11 ± 2.67 13.00 ± 4.12 15.25 ± 3.92 15.50 ± 2.93
Creatinine (mg/dL) 0.82 ± 0.20 0.80 ± 0.15 0.83 ± 0.18 0.86 ± 0.18
Blood urea nitrogen/creatinine ratio 14.93 ± 2.72 16.28 ± 5.01 18.39 ± 2.71 18.64 ± 5.40
White blood cell (K/mm3) 5.17 ± 0.77 5.09 ± 1.18 7.89 ± 2.01 7.40 ± 1.80
Red blood cell (M/mm3) 4.45 ± 0.32 4.49 ± 0.33 4.78 ± 0.25 4.74 ± 0.28
Hemoglobin (gm/dL) 13.74 ± 0.90 13.86 ± 0.91 13.69 ± 0.69 13.58 ± 0.71
Hematocrit (%) 40.87 ± 2.82 40.92 ± 2.51 41.23 ± 2.30 40.84 ± 2.28
Platelet count (K/mm3) 271.22 ± 59.16 269.78 ± 63.44 259.00 ± 70.07 276.13 ± 55.24
1Data are mean ± SD.
∗Significantly different from baseline (𝑃 < 0.05); T2DM: type 2 diabetes mellitus.
MDA and HNE were significantly decreased at 4 weeks
only in T2DM patients following pomegranate polyphenol
supplementation (Figure 2;𝑃 < 0.05).These results remained
significant when adjusted for the proportion of multivitamin
users in the diabetic group. However, pomegranate polyphe-
nol supplementation did not significantly affect CRP, a stable
biomarker of inflammation in healthy controls as well as in
T2DM patients (Figure 3).
No significant differences in dietary intakes of macro-
and micronutrients were noted at baseline and 4 weeks of the
intervention in healthy controls as well as in T2DM patients
(Table 5).
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Table 5: Dietary intakes1,2.
Nutrient Healthy controls (𝑛 = 9) T2DM subjects (𝑛 = 8)
Screen Week 4 Screen Week 4
Energy (kcal) 1679.42 ± 285.13 1739.05 ± 462.52 1266.32 ± 413.65 1273.38 ± 412.62
Protein (g) 70.71 ± 10.48 62.14 ± 15.29 60.74 ± 11.70 70.95 ± 23.45
Carbohydrate (g) 213.00 ± 45.42 254.90 ± 113.23 140.59 ± 50.55 129.42 ± 51.92
Fiber (g) 22.53 ± 5.33 19.75 ± 7.11 13.46 ± 4.83 12.11 ± 3.64
Total fat (g) 65.94 ± 16.21 55.62 ± 21.71 53.64 ± 22.81 54.98 ± 20.18
Saturated fat (g) 19.07 ± 6.40 15.74 ± 8.85 15.09 ± 7.05 18.91 ± 6.53
Monounsaturated fat (g) 17.18 ± 6.37 14.90 ± 7.80 13.71 ± 8.25 14.54 ± 7.11
Polyunsaturated fat (g) 12.36 ± 5.32 9.00 ± 5.03 9.91 ± 6.68 6.90 ± 5.07
Cholesterol (mg) 180.57 ± 69.85 144.51 ± 65.79 256.11 ± 179.52 236.83 ± 164.64
Carotenoids (RE) 773.01 ± 443.40 434.37 ± 240.67 486.79 ± 294.38 428.45 ± 207.05
Vitamin C (mg) 123.30 ± 55.90 278.77 ± 453.17 69.25 ± 44.85 51.61 ± 36.33
Vitamin E (mg) 6.66 ± 4.97 3.63 ± 2.36 5.05 ± 4.60 4.21 ± 5.46
Copper (mg) 0.99 ± 0.32 0.78 ± 0.40 0.60 ± 0.23 0.59 ± 0.23
Iron (mg) 13.82 ± 3.87 12.95 ± 3.06 9.85 ± 4.24 12.11 ± 6.02
Zinc (mg) 8.39 ± 2.24 7.30 ± 2.43 4.93 ± 1.85 7.43 ± 2.99
1Data are mean ± SD.
2Data summarized from 3-day food records; T2DM: type 2 diabetes mellitus.
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Figure 2: Serum malondialdehyde (MDA) and hydroxynonenal
(HNE) in healthy controls (𝑛 = 9) and in patients with type 2
diabetes (𝑛 = 8) before and after (4 weeks) pomegranate polyphenol
supplementation. Data presented as mean ± SD. ∗Significantly
different from baseline at 𝑃 < 0.05.
4. Discussion
Our study findings in healthy volunteers and in patients with
T2DM without complications provide evidence on the safety
and efficacy of a 4-week pomegranate polyphenol extract sup-
plementation. Our pre- and postintervention data analyses
show that POMx supplementation (2 capsules/day ∼1500mg
polyphenols) did not significantly alter safety parameters in
both groups of participants. However, we observed a specific
modulation of liver enzymes (AST and ALT) at 4 weeks
versus baseline, though values remained within the normal
clinical range defined in our study. POMx supplementation
did not affect body weight, blood pressure, glucose, and
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Figure 3: Serum C-reactive protein in healthy controls (𝑛 = 9)
and in patients with type 2 diabetes (𝑛 = 8) before and after (4
weeks) pomegranate polyphenol supplementation. Data presented
as mean ± SD.
lipids in healthy controls as well in T2DM patients. Among
the biomarkers of lipid oxidation and inflammation, POMx
supplementation significantly reduced MDA and HNE only
in T2DM patients, while oxidized LDL and serum CRP
were not significantly affected at 4 weeks in either group.
Overall, our study findings show modest effects of POMx
supplementation in improving lipid peroxidation, only in
diabetic patients versus baseline.
Type 2 diabetes (T2DM) is an overwhelming public
health concern and has been significantly associated with
elevated lipid oxidation and inflammation [14]. Observa-
tional data derived from the National Health Interview
Survey (NHIS) in the United States reveal a high prevalence
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of nonvitamin/nonmineral supplement use among adults
with T2DM, but no significant associations with disease
severity [15]. These observations identify the urgent need
for studies to examine the efficacy of dietary supplements
in improving clinical outcomes of T2DM, especially sup-
plements containing botanical ingredients, with claims in
health and disease. In case of pomegranate supplements,
clinical studies, though few, report some promising data
on their role in the therapeutic management of T2DM. In
an uncontrolled study for 4–6 weeks, pomegranate juice
and concentrates (∼650mg gallic acid equivalents) were
shown to significantly decrease TBARS and increase serum
thiols, thereby showing an improvement in oxidative stress
in diabetic patients.Though pomegranate intervention in this
study showed no effects in glucose and lipid levels, the activity
of paraoxonase 1 (PON1) associated with the antiatheroscle-
rotic activities of HDL was significantly increased follow-
ing pomegranate supplementation [16]. Similar antioxidant
effects of pomegranate juice in diabetic patients have also
been reported by other studies conducted by the same group
of researchers in Israel [6]. In another study reported from
Iran in T2DM patients with hyperlipidemia, concentrated
pomegranate juice supplementation (40 g for 8 weeks) was
shown to decrease total and LDL-cholesterol, but not HDL-
cholesterol and triglycerides versus baseline [17]. Thus, our
study findings of significant lowering of lipid peroxidation
with a 4-week POMx supplementation (2 capsules/day) in
diabetic patients, but with no effects on glucose and lipids,
conform to some of these previous clinical studies. However,
it should be noted that all of these studies, including ours,
were conducted using a small sample size with no placebo-
controlled group. In a single placebo-controlled study of
T2DM patients, a 3-month antioxidant supplementation
of a combination of pomegranate and green tea extracts
and ascorbic acid was shown to significantly reduce LDL-
cholesterol, increase HDL-cholesterol, and decrease lipid
peroxidation versus placebo [18]. However, the study did not
report safety profiles following antioxidant supplementation
and does not identify the effects of pomegranate polyphenols
per se.
The use of botanical supplements with health and disease
claims has been an issue of safety concerns. Researchers have
identified toxicities associated with dietary supplement use
as a result of deviations from good manufacturing practices,
including contamination with heavy metals and microbes, as
well as toxic effects of unidentified constituents in the sup-
plements [19]. Pomegranate polyphenol extracts (∼1400mg)
have been reported to be safe in a single randomized placebo-
controlled study reported byHeber et al. (2007) in overweight
subjects [11], and pomegranate juice supplementation (∼8 oz)
and higher dose of extracts (∼3000mg) have also shown
no adverse effects in phase II clinical trials in patients with
prostate cancer [20, 21]. However no such studies on clinical
safety profiles have been reported in patients with T2DM.
Thus, our novel findings show no significant adverse effects
of two capsules of POMx (∼1500mg polyphenols) for 4 weeks
in obese patients with T2DM. We observed a small but
significant decrease in hepatic ALT at 4 weeks though values
remained within the normal clinical range used in our study.
Keeping in view the short duration of our intervention, larger
placebo-controlled dose-response studies of longer duration
are needed to confirm the effects of pomegranate polyphenols
in T2DM patients with and without complications.
Few studies have examined the effects of pomegranate
polyphenols in nonobese healthy volunteers with no history
of chronic diseases. Pomegranate juice supplementation for
4 weeks has been reported to significantly reduce systolic
and diastolic blood pressure [22] and suppress high-fat meal-
induced postprandial rise in systolic blood pressure [23],
versus control groups in healthy volunteers. Interestingly, the
amount of pomegranate polyphenols administered in these
studies [22, 23] was lower than the dose used in our study.
Furthermore, in contrast to these previous studies, we did
not observe any significant changes in systolic and diastolic
blood pressure in our healthy volunteers at 4 weeks of
pomegranate polyphenol intervention. These discrepancies
might be explained by the sample size, dose and form of
delivery of pomegranate polyphenols (juice versus capsules),
and duration of the studies.
Our study has some limitations including a small sample
size of healthy volunteers andT2DMpatients and the absence
of dose-response effects and a no treatment control group. In
addition, we were unable to detect gender-wise differences
in our small study sample, and this would be of specific
relevance to lipid profiles following intervention. Further, we
did not include T2DM patients with complications, or those
on insulin therapy. Thus, our study in well-controlled T2DM
patients with no complications cannot be generalized to the
larger diabetic population.
5. Conclusion
We conclude that commercially available pomegranate
polyphenols (POMx 1500mg/day for 4 weeks, PomWonder-
ful, CA, USA) were well tolerated with no adverse effects
in healthy volunteers as well as in patients with type 2
diabetes. In addition, POMx lowered lipid peroxidation only
in diabetic patients but had no effects on glucose, lipids, and
C-reactive protein in either group of participants.
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